Welcome to the Clinerion website. This website uses cookies. These cookies are used on your browser to understand how you are using our website. Using this website means you agree to our use of cookies. If you prefer not to have these cookies on your device, we advise you to disable them in your web browser settings. You accept the use of cookies by accepting this notice. You can read more details via our Privacy Policy page.
Privacy Policy page >
Clinerion Ltd
Contact Details:
Main address:
Margarethenstrasse 47
4053
Basel, Switzerland
,
Tel:+41 61 865 60 60 ,
E-mail: info(at)clinerion.com
Website: Clinerion Website
Clinerion Patient Network Explorer
Clinerion Patient Network Explorer
Optimized study design, precise site selection and faster patient search and identification for clinical research - in real time.
Clinerion report: Assessment of the distribution of patients with atherosclerotic cardiovascular disease (ASCVD) and ASCVD risk factors among individuals with type-2 diabetes (T2DM) by using EHR data
A Single Center Real-Life Evidence Study in Turkey, with AstraZeneca and İnönü University
 |
It is predicted that the number of individuals with diabetes in the world will increase 55% to reach 592 million in 2035 while this number is 382 million as of 2013. Atherosclerotic cardiovascular disease (ASCVD) is one of the most important occurrences of morbidity and mortality in patients with diabetes. In this study, which has been designed with a single-center, retrospective research design, using electronic health record (EHR) data; it is aimed to detect the co-occurrence rates of T2DM and risk factors with real-life data. Please fill in the form below to gain access to this report. |
Personal Data Protection Statement
The information you provide allows us to provide you with information and updates on Clinerion’s products and services (the purpose). By submitting your details in the registration form, you give explicit consent that your personal details may be used for this and only this purpose by Clinerion and webinar partners, who may also provide you with information and updates on their products and services.
Clinerion, as the data controller and processor, will maintain the data for as long as the data is required for the purposes mentioned above, or until you withdraw consent as stated below. Personal data are not kept longer than necessary and are processed in a manner that ensures appropriate security and confidentiality, including for preventing unauthorized access to or use of personal data and the equipment used for the processing.
We will not sell or give away any personal information that you provide and only use it for the purposes stated above. You may request to view, correct, or delete your data in Clinerion’s database or withdraw consent by contacting info@clinerion.com. Please note that withdrawal of consent shall not affect the lawfulness of Clinerion’s use of your personal data for the purposes mentioned above before withdrawal of consent.
The legal address of Clinerion: Clinerion Ltd, Elisabethenanlage 11, 4051 Basel, Switzerland. e-Mail address info@clinerion.com.
